Atazanavir-d6
Modify Date: 2024-01-02 00:51:18
Atazanavir-d6 structure
|
Common Name | Atazanavir-d6 | ||
|---|---|---|---|---|
| CAS Number | 1092540-50-5 | Molecular Weight | 710.89 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C38H46D6N6O7 | Melting Point | 200-205°C | |
| MSDS | N/A | Flash Point | N/A | |
Use of Atazanavir-d6Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3]. |
| Name | trideuteriomethyl N-[(2S)-1-[2-[(2S,3S)-3-[[(2S)-3,3-dimethyl-2-(trideuteriomethoxycarbonylamino)butanoyl]amino]-2-hydroxy-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate |
|---|---|
| Synonym | More Synonyms |
| Description | Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3]. |
|---|---|
| Related Catalog | |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
| References |
[3]. Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96. |
| Melting Point | 200-205°C |
|---|---|
| Molecular Formula | C38H46D6N6O7 |
| Molecular Weight | 710.89 |
| Exact Mass | 710.42700 |
| PSA | 185.18000 |
| LogP | 6.30100 |
| Storage condition | -20C |
| [2H6]-Atazanavir |
| 2,5,6,10,13-Pentaazatetradecanedioic acid,3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-,1,14-di(methyl-d3) ester,(3S,8S,9S |
| 12S) |